U.S. Congress

Washington’s Drug Pricing Rules Could Squeeze Smaller Competitors
Washington’s push for PBM transparency could backfire if overlapping rules burden smaller competitors and strengthen the industry’s dominant firms.
09.25.26

Privacy Overview

International Policy Digest

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.